(+)-murrayazoline | 25488-37-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (+)-murrayazoline
• 英文别名: (14R,17S)-3,13,13,17-tetramethyl-21-oxa-12-azahexacyclo[10.7.1.12,17.05,20.06,11.014,19]henicosa-1,3,5(20),6,8,10-hexaene
• CAS: 25488-37-3
• 化学式: C₂₃H₂₅NO
• 分子量: 331.458
• InChiKey: YPSWCORASQDCJM-QKBBCMBSSA-N

物化性质

• 熔点：
  266 °C
• 沸点：
  477.0±45.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  14.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Synergistic composition for treating hyperilipdemia
  申请人：Pushpangadan Palpu

  公开号：US20050136138A1

  公开（公告）日：2005-06-23

  The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2-5 wt. %, Murraya koenigii of concentration ranging between 8-15 wt %, Allium sativum of concentration ranging between 2-4 wt %, Zingiber officinalis of concentration ranging between 2-5 wt %, Amorphophallus campanulatus of concentration ranging between 1-10%, and pharmaceutically acceptable additive(s); a process for the preparation of the said synergistic pharmaceutical composition; and also, a use of the said composition for treating hyperlipidemia, atherosclerosis, and obesity.

  本发明涉及一种协同作用的药物组合物，用于治疗高脂血症，该组合物包括浓度在2-5wt.%之间的龙胆（Gentiana kurroo）植物提取物，浓度在8-15wt.%之间的黄腺木（Murraya koenigii）植物提取物，浓度在2-4wt.%之间的大蒜（Allium sativum）植物提取物，浓度在2-5wt.%之间的生姜（Zingiber officinalis）植物提取物，浓度在1-10%之间的小蒟蒻（Amorphophallus campanulatus）植物提取物和药学上可接受的添加剂；一种制备该协同药物组合物的方法；以及使用该组合物治疗高脂血症、动脉硬化和肥胖症的用途。
• US6989165B2
  申请人：——

  公开号：US6989165B2

  公开（公告）日：2006-01-24
• [EN] A SYNERGISTIC COMPOSITION FOR TREATING HYPERLIPIDEMIA<br/>[FR] COMPOSITION SYNERGIQUE DE TRAITEMENT DE L'HYPERLIPIDEMIE
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2005070442A1

  公开（公告）日：2005-08-04

  The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2-5 wt. %, Murraya koenigii of concentration ranging between 8-15wt %, Allium sativum of concentration ranging between 2-4 wt %, Zingiber officinalis of concentration ranging between 2-5wt %, Amorphophallus campanulatus of concentration ranging between 1-10%, and pharmaceutically acceptable additive(s); a process for the preparation of the said synergistic pharmaceutical composition; and also, a use of the said composition for treating hyperlipidemia, atherosclerosis, and obesity.